Mpox Outbreak 

AIRA is closely monitoring ways to support the IIS community in responding to the mpox outbreak that began in May 2022. We are actively working with partners at the state and federal levels and engaging with IIS community members to identify solutions related to challenges with vaccine ordering; inventory and wastage tracking and reporting; shipping information; provider agreements; and reporting of vaccine administration data. This is a rapidly evolving response, and we will continue to compile and provide information as it becomes available. 

General Mpox Resources

• The Centers for Disease Control and Prevention (CDC) Mpox Landing Page: Main landing page linking to general information about the outbreak, prevention, epidemiology, clinical considerations, communications, and links to vaccination information

• CDC's Mpox Vaccine Administration in the U.S. webpage: Vaccine administration data on doses administered and reported to CDC

• CDC's Vaccine Administration U.S. Map: Mpox vaccination doses based on data reported to the CDC by U.S. jurisdictions

• Rates of Mpox Cases by Vaccination Status | Mpox | Poxvirus | CDC: Displays overall weekly rates of Mpox cases by vaccination status

• CDC and Administration for Strategic Preparedness and Response (ASPR) Mpox Vaccination Operational Planning Guide: US government national vaccination strategy to vaccinate against mpox to assist state, territorial, tribal, and local health officials in planning and response

• Food and Drug Administration Emergency Use Authorization for JYNNEOS Vaccine: Press release summarizing the emergency use authorization to allow for intradermal injection for individuals 18 years and older, increasing the number of doses available, as well as to allow for standard (subcutaneous) administration of JYNNEOS in individuals younger than 18 years

• Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Mpox Outbreak 

Mpox Vaccine Reporting Requirements 

Mpox Vaccination Program Provider Agreement: With use of the JYNNEOS or ACAM2000 vaccine provided at no cost by the US government (this vaccine), the provider and provider’s organization (Organization) will be deemed to have agreed to comply with the requirements of this Agreement. Any person accessing this vaccine is subject to compliance with the terms of this Agreement, including any updates to the Agreement.

Please refer to the CDC ISD Awardees SharePoint portal for the most recent and official guidance, including:

• CDC PPX Vaccination Reporting Specification (MVRS)
• CDC MPX Aggregate Vaccination Reporting Specification (MAVRS)
• Jurisdictions that are prohibited from submitting line-level data and signed a data use agreement for aggregate reporting should use the MAVRS.
• The recording and presentation from the office hours session on August 11 are available on the ISD Awardees SharePoint in the IIS All-Awardee Forum folder.

Contacts

• Be sure to subscribe and receive important updates and meeting notifications through the weekly IIS Info Brief by contacting [email protected].
• Contact the IZDL Help Desk with questions about reporting.
• To share questions and concerns or request support related to monkeypox from AIRA, please email [email protected].

Updated: 8/23/2022